TY - JOUR
T1 - Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia
T2 - A phase 3, randomized, controlled study
AU - Mohiuddin, Syed M.
AU - Pepine, Carl J.
AU - Kelly, Maureen T.
AU - Buttler, Susan M.
AU - Setze, Carolyn M.
AU - Sleep, Darryl J.
AU - Stolzenbach, James C.
PY - 2009/1/1
Y1 - 2009/1/1
N2 - Background: Patients with mixed dyslipidemia often require combination therapy to effectively control lipid abnormalities. This study compared the effects of combination therapy with ABT-335 (a new formulation of fenofibric acid) and simvastatin to ABT-335 and simvastatin monotherapies on lipid and nonlipid parameters in patients with mixed dyslipidemia. Methods: This was a phase 3, multicenter, randomized, double-blind, active-controlled study. A total of 657 patients with mixed dyslipidemia (low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL, triglycerides [TGs] ≥150 mg/dL, and high-density lipoprotein cholesterol [HDL-C]
AB - Background: Patients with mixed dyslipidemia often require combination therapy to effectively control lipid abnormalities. This study compared the effects of combination therapy with ABT-335 (a new formulation of fenofibric acid) and simvastatin to ABT-335 and simvastatin monotherapies on lipid and nonlipid parameters in patients with mixed dyslipidemia. Methods: This was a phase 3, multicenter, randomized, double-blind, active-controlled study. A total of 657 patients with mixed dyslipidemia (low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL, triglycerides [TGs] ≥150 mg/dL, and high-density lipoprotein cholesterol [HDL-C]
UR - http://www.scopus.com/inward/record.url?scp=57149105884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57149105884&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2008.08.027
DO - 10.1016/j.ahj.2008.08.027
M3 - Article
C2 - 19081418
AN - SCOPUS:57149105884
SN - 0002-8703
VL - 157
SP - 195
EP - 203
JO - American Heart Journal
JF - American Heart Journal
IS - 1
ER -